Pediatric Low Grade Glioma clinical trials

Explore recruiting pediatric low grade glioma clinical trials.

Recruiting pediatric low grade glioma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pediatric Low Grade Glioma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized and controlled phase II protocol in non NF1 pediatric and AYA (Adolescent and Young Adults) patients bearing a newly diagnosed low grade glioma with wild type BRAF gene comparing a daily oral MEK inhibitor (Trametinib) versus weekly vinblastine for 18 months. PLGG – MEKTRIC (Pediatric Low Grade Glioma – MEKinhibitor TRIal vs Chemotherapy)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE)

Denmark, Czechia, Austria, Sweden, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy

Germany, Belgium, Denmark, Spain, France, Ireland +10 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Pediatric Low Grade Glioma trials by city

Pediatric Low Grade Glioma clinical trials

Recruiting pediatric low grade glioma studies right now

Developing Fast Pediatric Imaging

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas

Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG

Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK

Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma

Also recruiting in Europe

Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE)

LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy

Pediatric Low Grade Glioma trials by city

Other conditions